Novartis AG NVS
145.46
2.75
1.93%
as of 25 Sep
- Market cap
- $264.3B
- P/E
- 21.8×
Follow NVS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.53 | 21.76 | 19.15 | 17.42 |
+8 more quarters Free account |
P/S ratio |
5.27 | 5.15 | 4.72 | 4.38 | |
P/FCF ratio |
19.67 | 18.08 | 17.34 | 14.35 | |
P/Operating CF |
50.76 | 79.33 | 118.08 | 37.59 | |
P/B ratio |
7.12 | 7.49 | 5.74 | 5.52 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.96 | 5.83 | 5.10 | 4.74 | |
EV/EBITDA |
14.99 | 14.65 | 12.62 | 11.65 | |
EV/Operating CF |
18.37 | 17.19 | 15.11 | 12.69 | |
EV/FCF |
22.27 | 20.44 | 18.76 | 15.54 | |
Quick Ratio |
0.55 | 0.53 | 0.76 | 0.59 | |
Current Ratio |
0.86 | 0.85 | 1.12 | 0.88 | |
Net Debt/EBITDA |
6.40 | 7.00 | 4.26 | 3.52 | |
Debt/Assets |
38.58% | 38.02% | 30.23% | 28.07% | |
Debt/Equity |
1.12 | 1.16 | 0.72 | 0.67 | |
Asset Turnover |
0.50 | 0.52 | 0.53 | 0.53 | |
Operating CF/Net income |
1.80 | 1.16 | 0.94 | 1.67 | |
Capex/Depreciation |
(0.50) | (0.68) | (0.59) | (0.60) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
19.04% | 20.26% | 22.82% | 20.50% | |
Selling, General and Administrative Expense of Revenue |
21.68% | 23.22% | 24.82% | 23.04% | |
Intangible Assets out of Total Assets |
0.56 | 0.57 | 0.50 | 0.51 | |
Share Based Compensation of Revenue |
1.79% | 2.24% | 2.16% | 1.87% | |
Graham Net Nets |
(0.18) | (0.18) | (0.13) | (0.14) | |
Graham Number |
57.44 | 56.75 | 62.36 | 62.03 | |
Earnings Yield |
4.25% | 4.60% | 5.22% | 5.74% | |
Free Cash Flow Yield |
5.08% | 5.53% | 5.77% | 6.97% | |
Revenue per Share |
7.85 | 7.08 | 7.15 | 7.45 | |
Operating CF per Share |
3.09 | 1.93 | 1.17 | 3.41 | |
Capex per Share |
(0.37) | (0.43) | (0.47) | (0.40) | |
Free Cash Flow per Share |
2.72 | 1.49 | 0.70 | 3.01 | |
Cash per Share |
4.04 | 3.65 | 5.98 | 5.06 | |
Shareholders Equity per Share |
22.02 | 20.39 | 24.01 | 23.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.02 | 20.39 | 24.01 | 23.24 | |
Free Cash Flow |
5,174.00 | 2,850.00 | 1,360.00 | 5,793.00 | |
Working Capital |
(4,397.00) | (4,767.00) | 3,182.00 | (3,802.00) | |
Capital Expenditures |
(708.00) | (826.00) | (904.00) | (778.00) | |
Net Current Asset Value |
(52,736.00) | (52,998.00) | (33,940.00) | (34,339.00) | |
EV/EBIT |
19.76 | 19.15 | 16.40 | 15.23 | |
Capex to Sales |
0.05 | 0.06 | 0.07 | 0.05 | |
Net Profit Margin |
21.83% | 23.34% | 17.38% | 27.36% | |
Price to Operating Income |
17.46 | 16.94 | 15.15 | 14.07 | |
| Other line items | |||||
Average Receivables |
9,515.00 | 9,163.50 | 8,349.00 | 8,567.00 | |
Average Payables |
4,382.00 | 4,291.50 | 4,514.00 | 4,321.00 | |
Average Inventory |
6,263.50 | 6,057.50 | 5,996.00 | 6,180.00 | |
Average Assets |
113,214.00 | 109,236.50 | 106,597.50 | 105,406.50 | |
Average Common Equity |
42,000.00 | 38,689.50 | 45,337.50 | 44,096.50 |
Columns are period end dates